

**Maternal late-pregnancy serum unmetabolized folic acid concentrations are not associated with infant allergic disease - A prospective cohort study**

Karen P Best<sup>1,2</sup>, Tim J Green<sup>1,2</sup>, Dian Sulistyoningrum<sup>1,2</sup>, Thomas R Sullivan<sup>1,3</sup>, Susanne Aufreiter<sup>4,5</sup>, Susan L Prescott<sup>6,7,9</sup>, Maria Makrides<sup>1,2</sup>, Monika Skubisz<sup>1</sup>, Deborah L O'Connor<sup>4,5</sup>, Debra J Palmer<sup>8,9</sup>

<sup>1</sup> Women and Kids Theme, South Australian Health and Medical Research Institute, Adelaide, Australia

<sup>2</sup> Adelaide Medical School, Faculty of Health and Medical Sciences, The University of Adelaide, Australia

<sup>3</sup> School of Public Health, University of Adelaide, Australia

<sup>4</sup> Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada

<sup>5</sup> Translational Medicine, Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada

<sup>6</sup> The ORIGINS Project, Telethon Kids, Nedlands, WA, Australia

<sup>7</sup> Department of Immunology, Perth Children's Hospital, Nedlands, WA, Australia

<sup>8</sup> Telethon Kids Institute, The University of Western Australia, Nedlands, WA, Australia

<sup>9</sup> School of Medicine, The University of Western Australia, Crawley, WA, Australia

**Authors' Last: Best, Green, Sullivan, Sulistyoningrum, Aufreiter, Prescott, Makrides, O'Connor, Skubisz, Palmer**

**Corresponding Author:** Karen P Best  
South Australian Health and Medical Research Institute  
North Terrace  
Adelaide, South Australia, 5000  
[Karen.best@sahmri.com](mailto:Karen.best@sahmri.com)

**Sources of Support:** This work was supported by a Thrasher Researcher Foundation Early Career Award Program Grant, the National Health and Medical Research Council (NHMRC) of Australia: Project Grant (APP1046036) and NHMRC fellowships awarded to MM (APP1061704) and DJP (APP1144544). KPB is supported by Women's and Children's Hospital Foundation, MS McLeod Post-doctoral Fellowship. DCS is supported by The Australian Government Research Training Program Scholarship from The University of Adelaide.

**Short running head:** Prenatal unmetabolized folic acid and infant allergy

**Abbreviations:** unmetabolized folic acid (UMFA); neural tube defects (NTDs); dihydrofolate reductase (DHFR); Immunoglobulin-E (IgE); skin prick test (SPT);

1 **Abstract:**

2 **Background:** The increase in childhood allergic disease in recent decades has coincided with  
3 increased folic acid intakes during pregnancy. Circulating unmetabolized folic acid (UMFA)  
4 has been proposed as a biomarker of excessive folic acid intake.

5 **Objective:** We aimed to determine if late-pregnancy serum UMFA and total folate  
6 concentrations were associated with allergic disease risk in the offspring at one year of age in  
7 a population at high risk of allergy.

8 **Methods:** The cohort consisted of 561 mother-infant pairs from Western Australia. To be  
9 eligible the infant had a first-degree relative (mother, father or sibling) with a history of  
10 medically diagnosed allergic disease. Maternal serum was collected between 36 and 40 weeks  
11 of gestation. UMFA concentrations were measured by tandem mass spectrometry using stable  
12 isotope dilution, folate concentrations were determined using the microbiological method  
13 with standardized kits. Infant allergic disease outcomes of medically diagnosed eczema,  
14 steroid treated eczema, atopic eczema, IgE-mediated food allergy, allergen sensitization and  
15 medically diagnosed wheeze were assessed at 1 year of age.

16 **Results:** Median (IQR) for UMFA and serum folate was 1.6 (0.6-4.7) and 53.2 (32.6-74.5)  
17 nmol/L, respectively. Of the infants, 34.6% had medically diagnosed eczema, 26.4% allergen  
18 sensitization and 14.9% had an IgE-mediated food allergy. In both adjusted and unadjusted  
19 models there was little evidence of association between UMFA or serum folate and any of the  
20 infant allergy outcomes.

21 **Conclusion:** In this cohort of children at high risk for allergic disease there was no  
22 association between maternal UMFA or serum folate measured in late pregnancy and allergic  
23 disease outcomes at 1 year of age.

- 24 **Keywords:** unmetabolized folic acid; allergic disease; atopic dermatitis; eczema; food
- 25 allergy; folate; folic acid; infant; pregnancy.

## 26 **Introduction**

27 The prevalence of early childhood atopic diseases, predominately atopic dermatitis (eczema)  
28 and food allergy, have increased over recent decades. There is emerging evidence that  
29 immune function at birth is predictive of whether a child will develop allergic disease (1-4).

30 Therefore, the in-utero period may be critical in determining immune development  
31 trajectories towards an allergic phenotype (1, 5) and maternal diet during pregnancy could be  
32 a potential modifiable early life influence of allergic disease development.

33 This increase in early life allergic diseases has coincided with an increase in folic acid intake  
34 during the perinatal period. Women are advised to take folic acid containing supplements (6,  
35 7) prior to and during early pregnancy to reduce the incidence of neural tube defects (NTDs).  
36 (8-10) In addition, to further reduce NTDs, more than 80 countries worldwide have mandated  
37 the addition of folic acid to food staples such as flour. (11) NTDs occur in the first month of  
38 pregnancy, yet many women continue to take folic acid-containing supplements throughout  
39 pregnancy with no known benefit.

40 Folic acid is a synthetic form of folate; due to its high bioavailability, stability and low cost, it  
41 is used in supplements and for food fortification. Once consumed, folic acid is normally  
42 converted to tetrahydrofolate, by the enzyme dihydrofolate reductase (DHFR), before being  
43 further converted to 5-methyltetrahydrofolate. Higher intakes of folic acid can saturate the  
44 capacity of DHFR leading to the presence of unmetabolized folic acid (UMFA) in circulation.  
45 (29-32). Circulating UMFA has been detected in pregnant women and in cord blood (33-36).  
46 There is speculation that UMFA in circulation is a biomarker of excessive folic acid intake  
47 and may be causing harm through epigenetic changes to fetal gene expression, with  
48 subsequent increased disease risk (37, 38).

49 Animal models have shown that pregnant mice fed diets high in folic acid exhibit altered  
50 expression of immune genes through changes in DNA methylation in the offspring. Such  
51 changes have been associated with enhanced severity of allergic airway disease. (12)

52 Several observational cohort studies have reported inconsistent associations between higher  
53 prenatal folic acid or folate intakes and risk of allergic disease in the offspring (13-16) (17-27)  
54 however many rely on dietary assessment to measure exposure. Of the studies that examined  
55 biomarkers to determine exposure, only one differentiated between specific forms of folate  
56 (20). This nested case control study from the United States, reported that UMFA  
57 concentrations in cord blood were associated with an increased risk of food allergy, but not  
58 food allergen sensitization, however other allergic disease outcomes were not reported. (21)

59 Australia is an ideal setting to examine associations between folic acid in pregnancy and  
60 allergic disease outcomes in the offspring. It has among the highest prevalence of allergic  
61 disorders in the developed world in addition to high prenatal folic acid exposures from food  
62 fortification and high rates of prenatal folic acid supplementation. (28, 29) To date, no studies  
63 have examined the association between maternal late gestation UMFA and infant allergic  
64 disease. We aimed to determine if maternal serum UMFA or folate concentrations in late  
65 pregnancy predicted infant allergic disease outcomes at one year of age, in a pregnancy cohort  
66 of women carrying a fetus at high hereditary risk of allergic disease (history of allergic  
67 disease in at least one immediate family member).

## 68 **Methods**

### 69 *Study Population*

70 The data presented here come from mother-infant pairs from a prospective cohort study in  
71 Perth, Western Australia. The study was designed to explore whether maternal diet, lifestyle  
72 and environmental factors influence offspring susceptibility to allergic disease. Pregnant

73 women >18 years of age whose unborn infant had a first-degree relative (mother, father or  
74 sibling) with a history of medically diagnosed allergic disease (asthma, allergic rhinitis,  
75 eczema and/or food allergy) were recruited from local participating maternity antenatal clinics  
76 and classes between November 2011 and December 2016. Women were >36 weeks gestation  
77 at enrolment, with a singleton pregnancy, non-smokers (while pregnant) and healthy with no  
78 known complications (including immunodeficiency, pre-eclampsia, and major congenital  
79 anomalies). The original cohort study was approved by the Princess Margaret Hospital  
80 Human Research Ethics Committee (1942EP), and all participants provided written informed  
81 consent. The maternal blood analysis for this study was also approved by the Women's and  
82 Children's Health Network Human Research Ethics Committee in 2019  
83 (HREC/19/WCHN/21).

84 The investigators in the original cohort aimed to have around 600 mother–infant pairs with  
85 infant allergy outcomes at one year of age. This was based on previous cohorts which have  
86 examined associations between maternal diet in pregnancy and allergic disease outcomes in  
87 infants with a high hereditary risk of allergic disease. (18, 30)

### 88 ***Maternal Data and Blood Collection***

89 Maternal baseline data were collected between 36 and 40-weeks' gestation, including history  
90 of allergic disease, education, ethnicity, parity, and pet ownership (cat, dog, or both).

91 Maternal non-fasting blood samples were collected from the cubital vein into a serum clot  
92 activator tube (Vacuette, Z Serum Clot activator; Greiner Bio-One GmbH, Kremsmünster,  
93 Austria). The blood samples were allowed to clot, spun at 4000rpm for 10 minutes, serum was  
94 aliquoted into 1-2ml tubes and stored at -80°C until analyzed.

95

96 ***Infant Allergic Disease Assessment and Definitions***

97 At one year of age the participating infants were assessed at the Princess Margaret Hospital in  
98 Perth, Australia. A parent was asked if the infant ever had eczema which was diagnosed by a  
99 medical doctor (medically diagnosed eczema) during the first year of life, and if the eczema  
100 skin lesions were responsive to topical steroid treatment prescribed by a medical doctor  
101 (steroid treated eczema). The parent was also asked if the infant had any wheeze symptoms  
102 which had been diagnosed by a medical doctor (medically diagnosed wheeze).  
103 Immunoglobulin-E (IgE) -mediated food allergy was based on history of immediate IgE-  
104 mediated symptoms (within 60 minutes of food ingestion) including angioedema, urticaria,  
105 cough, wheeze, stridor, vomiting, diarrhea, cardiovascular symptoms, and allergen  
106 sensitization to the same food detected by positive skin prick test (SPT) at the one year of age  
107 visit. SPT was conducted to detect allergen sensitization to common Australian food and  
108 environmental allergens including cow's milk, hen's egg, peanut, cashew nut, wheat, rye  
109 grass, house dust mite, and cat (Hollister-Stier Laboratories, Spokane, WA, USA), as well as  
110 histamine as a positive control. A response was considered positive if the mean of the  
111 horizontal and perpendicular wheal diameter was 3 mm or greater in size than the mean wheal  
112 of the negative control site at 15 minutes. Sensitization was defined as a positive skin prick  
113 test result to at least one of the allergens assessed. Each infant's SPT and clinical allergy  
114 assessment results were confirmed by the research physician. Infant birth details (including  
115 delivery mode, gestational weight, gestational age and infant sex) were also collected.

116 ***Serum Unmetabolized Folic Acid (UMFA)***

117 Between August 2019 and July 2020 maternal serum samples were analyzed for UMFA by  
118 stable isotope dilution-Tandem mass spectrometry following the methods of Pfeiffer et.al.  
119 (31) using spectrometrically verified standards of folic acid and an internal standard of <sup>13</sup>C<sub>5</sub>-  
120 folic acid (Merck, Switzerland). Briefly, samples and standard spiked with folic acid-[<sup>13</sup>C<sub>5</sub>]

121 in 1 % ammonium formate, 0.5% ascorbic acid buffer (pH 3.2) were loaded onto phenyl  
122 cartridges (1mL) (Phenomenex, Torrance. CA) previously conditioned with 2 mL each of  
123 methanol, acetonitrile and 1 % ammonium formate buffer (pH 3.2) and were allowed to  
124 equilibrate for 1 minute. The loaded cartridges were washed sequentially with 3mL of 0.05 %  
125 ammonium formate buffer (pH=3.4, 0.25% ascorbic acid), and folic acid was eluted from the  
126 columns using an elution buffer (0.5mL) of 49% water, 40% methanol, 10% acetonitrile, 1%  
127 concentrated acetic acid and 0.5% ascorbic acid. Eluted samples were stored at -80 °C until  
128 analysis by tandem mass spectrometry at The Analytical Facility for Bioactive Molecules,  
129 The Hospital for Sick Children, Toronto, Canada.

130 Eluted solutions were separated chromatographically on a Kinetex PFP (50 x 3.0 mm, 2.6 µm  
131 particle size) column (Phenomenex, Torrance CA). The mass-to-charge ratios of the  
132 transitions of interest, m/z 442.4 → m/z 295.1 for folic acid and m/z 447.4 → 495.1 for 13C  
133 folic acid, were monitored using an AB Sciex QTRAP 5500 triple quadrupole MS system  
134 (Agilent 1290 UHPLC system, (Agilent Technologies, Santa Clara, CA, USA

135 The inter-batch accuracy and precision were determined with the use of NIST 1950 Standard  
136 Reference Material with a certified value of  $1.51 \pm 0.45$  ng/mL. Each group of samples was  
137 analyzed along with an aliquot of the reference material NIST1950, Metabolites in Frozen  
138 Human Plasma; the mean ( $\pm$ SD) obtained for 12 batches of samples was  $1.80 \pm 0.21$  ng/mL,  
139 with a CV of 11.9%. Some UMFA concentrations were below the limit of detection and were  
140 set to the mid-point between 0 and the detection limit for analysis. and were set to the mid-  
141 point between 0 and the detection limit for analysis.

#### 142 *Serum folate*

143 Serum folate concentrations were determined using the microbiological method based on the  
144 technique of O'Broin and Kelleher, using standardized kits from the US Centers for Disease

145 Control and Prevention (Atlanta, GA).[18–20] This method uses 96 well microplates, 5-  
146 methyl tetrahydrofolate (Merck) as the calibrator, and chloramphenicol resistant *Lactobacillus*  
147 *rhamnosus* (ATCC® 27773™) as the test organism. High- and low-quality controls for serum  
148 folate provided by the Centers for Disease Control were run in quadruplets on every plate.

#### 149 *Statistical Analysis*

150 Associations between the maternal folate measures and infant allergy outcomes were  
151 evaluated using logistic regression, with effects described as odds ratios with 95% confidence  
152 intervals. UMFA and serum folate concentrations were treated as continuous exposures in the  
153 main analysis, with the assumption of a linear association with the log odds of each allergic  
154 disease outcome assessed using Hosmer-Lemeshow tests. For completeness, additional  
155 analyses were also performed with the UMFA and folate measures grouped into quartiles and  
156 treated as categorical exposures. For each outcome variable and UMFA and folate measure,  
157 both unadjusted and adjusted analyses were performed, with adjustment for maternal age,  
158 further maternal education after high school, maternal Caucasian ethnicity, maternal cat/dog  
159 ownership, maternal parity > 1, vaginal delivery, infant sex, infant birth weight, and infant  
160 gestational age at birth. (32) UMFA concentrations below the limit of detection were set to  
161 the mid-point between 0 and the detection limit for analysis. All statistical analyses were  
162 performed using Stata version 16.0 (College Station, TX: StataCorp LP).

## 163 **Results**

### 164 *Study Population*

165 561 mother–infant pairs with complete maternal data, maternal blood sample and at least one  
166 of the infant allergic disease outcome measures were included in this analysis. Maternal and  
167 infant characteristics for the mother–infant pairs are summarized in **Table 1**. The majority of  
168 the participating women were European Caucasian (91%) and most had completed post-

169 secondary school education (75%). All infants had at least one immediate family member  
170 (first-degree relative) with a history of allergic disease and 92% had maternal allergic disease.

171 *Maternal serum unmetabolized folic acid and folate concentrations*

172 In late gestation, UMFA was detectable in 520/559 (93.0%) of maternal serum samples, with  
173 concentrations ranging from 0.03 to 244.7 (median 1.6; IQR 0.6 to 4.7) nmol/L. Maternal  
174 serum folate concentration ranged from 4.3 to 185.0 (median 53.2; IQR 32.6 to 74.5) nmol/L.  
175 The Spearman rank correlation coefficient between the UMFA and serum folate  
176 concentrations was 0.50 (95% CI 0.44 to 0.57).

177 *Infant allergic disease outcomes*

178 Of the infants, 194/561 (34.6%) had medically diagnosed eczema and 150/561 (26.7%) had  
179 eczema requiring steroid treatment during the first year of life. The allergen sensitization rate  
180 was 26.4% (146/552), with 14.9% (83/558) of infants classified as having atopic eczema  
181 (medically diagnosed eczema and allergen sensitization) and 14.9% (83/558) of infants with  
182 an IgE-mediated food allergy. Only 8.7% (49/561) infants had medically diagnosed wheeze  
183 during infancy.

184 No associations were found between maternal UMFA (**Table 3**) or folate concentrations  
185 (**Table 3**) and infant allergic disease outcomes. In the case of UMFA, results weren't sensitive  
186 to the method used to deal with values below the detection limit (set to the limit, set to 0 or  
187 excluded from analysis, results didn't change). Similarly, we did not find any associations  
188 between maternal UMFA quartiles (**Table 4**) or folate quartiles (**Table 5**) and any of the  
189 infant allergic disease outcomes in additional adjusted and unadjusted (not shown) analyses.

190

191 **Discussion**

192 This is the first prospective cohort study to examine the association between maternal late  
193 pregnancy UMFA status and multiple allergic disease outcomes in a ‘high-risk’ infant  
194 population. We found no evidence of associations between maternal UMFA or folate  
195 concentrations and any infant allergic disease outcomes.

196 One other cohort study has examined the association between UMFA and childhood allergy  
197 outcomes using cord blood to measure exposure. (20) In contrast to our findings, McGowan  
198 et. al. reported that children whose cord blood concentrations were in the highest quartile of  
199 UMFA (n=14/33) had an 8.5-fold (95% CI 1.7 to 42.8) increased risk of confirmed food  
200 allergy compared to the lowest quartile. (20) However, interestingly there was no association  
201 between UMFA and food allergen sensitization. Furthermore, atopic dermatitis/eczema  
202 outcomes (the most common allergic disease in infancy) were not reported. Given there was  
203 only 6.6% (33/502 children with cord blood UMFA) of the children with confirmed food  
204 allergy in the McGowan et. al. publication, and the wide confidence interval, there is a  
205 possibility of this being a chance finding. Our Australian based study differed from this US  
206 study in several ways. Notably, our cohort had higher rates of offspring food allergy (14.9%  
207 vs 6.6%). In addition, our population included mostly women of European Caucasian  
208 ethnicity (91%), whereas, the Boston Birth Cohort in the study by McGowan et. al. were  
209 predominately of non-Hispanic black ethnicity (only 7% ‘white’). We cannot compare our  
210 UMFA concentrations in maternal serum to those reported in cord blood samples in the study  
211 by McGowan et al. However, the prevalence and range of detectable concentrations of UMFA  
212 in our maternal study population (93%, range: undetectable to 245nmol/L) are similar to those  
213 reported by Plumptre et. al. from blood samples collected from women in early pregnancy  
214 (56% Caucasian) and taking a folic acid containing supplement (97%; range undetectable to  
215 244 nmol/L). (33)

216 We also found no association between maternal serum folate at 36-40 weeks' gestation and  
217 infant allergic disease outcomes even though we did find higher median maternal serum folate  
218 concentrations (53.2 (IQR 32.6-74.5) nmol/L), compared to a previous Western Australian  
219 cohort study (n=435), where average serum folate concentrations were 37.2 nmol/l (IQR  
220 25.6–50.5 nmol/l) after 28 weeks gestation. (18) The previous Western Australian cohort  
221 study also did not find any associations between maternal serum folate concentrations and  
222 infant eczema outcomes, but did find that cord blood folate concentrations <50 nmol/l (OR =  
223 3.02; 95% CI 1.16–7.87) and >75 nmol/l (OR = 3.59; 95% CI 1.40–9.20) were associated  
224 with greater infant allergen sensitization risk than cord blood folate concentrations between  
225 50 and 75 nmol/l. (18)

226 Previous findings from observational studies examining associations between folate exposure  
227 in pregnancy from food and/or supplement use and offspring allergic disease have been  
228 equivocal, the majority reporting an increased risk, (13-16) (17-23); some no association, (24,  
229 25) and others suggesting a protective effect of folate (26, 27). Two studies suggested a “U  
230 shaped distribution” association where both high and low folate exposure increased allergy  
231 risk (19, 33), however we could not find any similar associations in our study. The  
232 inconsistency in results may be due to heterogeneity of populations studied including genetic  
233 differences and background folate intakes from food. Study design differences including;  
234 timing and classification (i.e. diet, supplement use, or folate biomarkers) of folate/folic acid  
235 exposure, as well as offspring age and types of allergic disease outcomes assessed may also  
236 confound results. Many of the observational studies showing associations between folic acid  
237 and allergic disease have relied on maternal reported folic acid supplementation or dietary  
238 assessment methods as the exposure, which can be subject to reporting bias and measurement  
239 error. Furthermore, folic acid supplements are usually consumed as part of a multi-vitamin  
240 and mineral supplement and hence it is impossible to determine the independent effect of folic

241 acid. In our study there was no association between late pregnancy supplement use and risk of  
242 allergic disease despite 86% of participants taking folic acid containing supplements.

243 A strength of our study is the objective measurement of serum UMFA and folate  
244 concentrations which reduce potential reporting bias due to reliance on participant memory of  
245 dietary intake of folate from foods or supplement use. However, the pregnant women in our  
246 study were not fasted and the timing of the maternal blood sample collection in relation to the  
247 last ingestion of maternal folic acid supplementation is unknown. UMFA rises rapidly after  
248 ingesting folic acid and falls steadily over time. Our cohort of infants at high hereditary risk  
249 of allergic disease increased our incidence of allergy outcomes compared to studies in a  
250 general population. However, we cannot exclude the fact that these infants with a genetic  
251 tendency towards atopy may have a predetermined disposition to an allergic phenotype which  
252 may not be modifiable by maternal folic acid concentration.

253 We controlled for a number of important confounders including those known to be associated  
254 with allergy risk, but as with any epidemiological study, the possibility of confounding  
255 remains. As an example, as with the incidence of allergic disease (34), higher folic acid  
256 supplement use has also been associated with higher socioeconomic status. Moreover, as  
257 folic acid is usually taken as part of a multi-vitamin and mineral preparation, other nutrients  
258 also may influence allergy outcomes both positive and negative.

259 In conclusion, we found no associations between maternal late gestation serum UMFA or  
260 folate levels and risk of infant allergic disease at one year of age in a population with high  
261 hereditary risk of atopy. Further work, including randomized controlled trials with objective  
262 biomarkers are needed to confirm that high folic acid exposure during late pregnancy, largely  
263 driven by the combination of food fortification and prenatal folic acid supplement use, does  
264 not increase the risk of childhood allergic disease in the general population.

265 **Acknowledgements:** We would like to acknowledge the women and children who  
266 participated in the cohort study, and associated research team staff who have made this work  
267 possible.

268 **Conflict of Interest (COI) Statement:**

- 269 • Prof. Makrides reports scientific board membership of Trajan, outside the submitted  
270 work.
- 271 • Prof. Prescott reports personal fees from Danone Nutricia, personal fees from Bayer,  
272 personal fees from Swisse Advisory Board, personal fees from Sanofi, outside the  
273 submitted work
- 274 • Dr. Best, Prof. Green, Ms Sulistyoningrum, Dr Sullivan, Dr. Aufreiter, Dr Skubisz,  
275 Prof. O'Connor and Dr Palmer have no conflicts of interest to disclose.

276 **Authors' contributions to the manuscript:** KPB, TJG, DJP, MM, MS and TRS designed  
277 this research project. KPB provided day to day study oversight; DS and SA conducted  
278 analysis of samples with oversight from TS and DLO. SLP and DJP provided maternal blood  
279 samples and maternal and infant data, including the allergic disease outcome data. TRS  
280 performed statistical analysis; KPB drafted the manuscript with input from TJG and DJP. All  
281 authors reviewed the manuscript for final content.

**Table 1.** Descriptive statistics for maternal and infant characteristics

<b>Characteristic</b>	<b>Total N=561</b>
Maternal age (years)	32.9 (4.8)
Maternal allergic disease	517/560 (92.3%)
Maternal positive skin prick test	482/537 (89.8%)
Maternal atopy	467/560 (83.4%)
Maternal European Caucasian ethnicity	493/544 (90.6%)
Further maternal education after secondary school	417/558 (74.7%)
Maternal dog and/or cat ownership	334/559 (59.7%)
Maternal parity > 1	296/560 (52.9%)
Maternal late pregnancy vitamin use	457/528 (86.6%)
Maternal dietary folate intake at 32-36 weeks gestation (mg/day)	265 (212-329)
Vaginal delivery	372/550 (67.6%)
Infant GA at birth (weeks) [n=550]	39.3 (1.1)
Infant birth weight (grams) [n=559]	3502 (434)
Female infant sex	271/561 (48.3%)

Data are presented as mean (SD) or median (IQR) for continuous measures, and n/total (%) for categorical measures. GA, gestational age.

**Table 2.** Associations between unmetabolized folic acid concentration (continuous) and infant allergic disease outcomes<sup>1</sup>

<b>Outcome</b>	<b>Unadjusted odds ratio (95% CI)</b>	<b>P-value</b>	<b>Adjusted<sup>2</sup> odds ratio (95% CI)</b>	<b>Adjusted p-value</b>
Medically diagnosed eczema	0.99 (0.89, 1.09)	0.77	1.02 (0.90, 1.15)	0.76
Steroid treated eczema	1.02 (0.93, 1.13)	0.66	1.04 (0.92, 1.18)	0.54
Atopic eczema	1.05 (0.94, 1.17)	0.39	1.06 (0.92, 1.22)	0.44
IgE mediated food allergy	1.04 (0.93, 1.16)	0.52	1.05 (0.91, 1.21)	0.52
Allergen sensitization	1.02 (0.92, 1.13)	0.74	1.02 (0.90, 1.16)	0.77
Medically diagnosed wheeze	1.08 (0.96, 1.21)	0.22	1.13 (0.96, 1.34)	0.14

<sup>1</sup> Odds ratios describe the effect of a 10 nmol/L increase in unmetabolized folic acid; goodness of fit confirmed using Hosmer Lemeshow tests

<sup>2</sup> Adjusted for maternal age, further maternal education after high school, maternal Caucasian ethnicity, infant sex, infant birth weight, infant GA at birth, maternal cat/dog ownership, parity > 1 and vaginal delivery

**Table 3.** Associations between serum folate (continuous) and infant allergic disease outcomes<sup>1</sup>

<b>Outcome</b>	<b>Unadjusted odds ratio (95% CI)</b>	<b>P-value</b>	<b>Adjusted<sup>2</sup> odds ratio (95% CI)</b>	<b>Adjusted p-value</b>
Medically diagnosed eczema	0.99 (0.94, 1.05)	0.81	1.00 (0.95, 1.06)	0.93
Steroid treated eczema	1.01 (0.96, 1.07)	0.69	1.01 (0.95, 1.07)	0.76
Atopic eczema	1.04 (0.97, 1.11)	0.27	1.03 (0.96, 1.10)	0.43
IgE mediated food allergy	0.95 (0.88, 1.02)	0.16	0.93 (0.86, 1.00)	0.07
Allergen sensitization	1.00 (0.95, 1.06)	0.87	0.99 (0.94, 1.05)	0.78
Medically diagnosed wheeze	1.02 (0.94, 1.11)	0.57	1.03 (0.95, 1.12)	0.51

<sup>1</sup> Odds ratios describe the effect of a 10 nmol/L increase in serum folate; goodness of fit confirmed using Hosmer Lemeshow tests

<sup>2</sup> Adjusted for maternal age, further maternal education after high school, maternal Caucasian ethnicity, infant sex, infant birth weight, infant GA at birth, maternal cat/dog ownership, parity > 1 and vaginal delivery

**Table 4.** Associations between unmetabolized folic acid concentration (quartiles) and infant allergic disease outcomes

Outcome	Quartile <sup>1</sup>	N (%)	Adjusted <sup>2</sup> odds ratio (95% CI)	P-value <sup>3</sup>
Medically diagnosed eczema	1	53/141 (37.6)	1 (Ref)	<b>0.63</b>
	2	48/139 (34.5)	0.98 (0.58, 1.65)	0.94
	3	52/140 (37.1)	1.05 (0.62, 1.77)	0.86
	4	41/139 (29.5)	0.76 (0.44, 1.29)	0.31
Steroid treated eczema	1	44/141 (31.2)	1 (Ref)	<b>0.71</b>
	2	34/139 (24.5)	0.74 (0.42, 1.29)	0.29
	3	35/140 (25.0)	0.78 (0.45, 1.36)	0.38
	4	37/139 (26.6)	0.78 (0.45, 1.35)	0.37
Atopic eczema	1	19/140 (13.6)	1 (Ref)	<b>0.65</b>
	2	23/138 (16.7)	1.39 (0.68, 2.86)	0.37
	3	21/139 (15.1)	1.47 (0.71, 3.04)	0.30
	4	20/139 (14.4)	1.07 (0.51, 2.25)	0.85
IgE mediated food allergy	1	20/141 (14.2)	1 (Ref)	<b>0.36</b>
	2	27/137 (19.7)	1.47 (0.74, 2.92)	0.27
	3	18/140 (12.9)	0.91 (0.43, 1.93)	0.81
	4	18/138 (13.0)	0.82 (0.39, 1.72)	0.59
Allergen sensitization	1	35/139 (25.2)	1 (Ref)	<b>0.74</b>
	2	42/137 (30.7)	1.27 (0.71, 2.26)	0.42
	3	33/137 (24.1)	0.98 (0.54, 1.78)	0.94
	4	36/137 (26.3)	0.94 (0.52, 1.70)	0.84
Medically diagnosed wheeze	1	8/141 (5.7)	1 (Ref)	<b>0.12</b>

2	11/139 (7.9)	1.55 (0.56, 4.30)	0.40
3	14/140 (10.0)	2.33 (0.84, 6.45)	0.10
4	16/139 (11.5)	3.07 (1.15, 8.21)	0.03

<sup>1</sup> Quartile 1 <0.66 nmol/L; Q2 0.66 to 1.65 nmol/L; Q3 1.65 to 4.69 nmol/L; Q4 > 4.69 nmol/L

<sup>2</sup> Adjusted for maternal age, further maternal education after high school, maternal Caucasian ethnicity, infant sex, infant birth weight, infant GA at birth, maternal cat/dog ownership, parity > 1 and vaginal delivery

<sup>3</sup> Bolded p-values are for the global null hypothesis that the log odds of allergic disease are the same in the four quartiles

**Table 5.** Associations between serum folate (quartiles) and infant allergic disease outcomes

Outcome	Quartile <sup>1</sup>	N (%)	Adjusted <sup>2</sup> odds ratio (95% CI)	P-value <sup>3</sup>
Medically diagnosed eczema	1	48/141 (34.0)	1 (Ref)	<b>0.59</b>
	2	48/140 (34.3)	1.13 (0.66, 1.92)	0.66
	3	53/140 (37.9)	1.38 (0.82, 2.33)	0.23
	4	45/140 (32.1)	1.01 (0.60, 1.71)	0.97
Steroid treated eczema	1	36/141 (25.5)	1 (Ref)	<b>0.78</b>
	2	35/140 (25.0)	1.06 (0.59, 1.89)	0.84
	3	40/140 (28.6)	1.33 (0.76, 2.32)	0.32
	4	39/140 (27.9)	1.12 (0.64, 1.97)	0.68
Atopic eczema	1	21/141 (14.9)	1 (Ref)	<b>0.91</b>
	2	18/138 (13.0)	0.96 (0.46, 2.00)	0.91
	3	19/139 (13.7)	0.96 (0.47, 1.98)	0.92
	4	25/140 (17.9)	1.20 (0.60, 2.38)	0.61
IgE mediated food allergy	1	27/140 (19.3)	1 (Ref)	<b>0.29</b>
	2	20/138 (14.5)	0.76 (0.38, 1.52)	0.43
	3	18/140 (12.9)	0.62 (0.31, 1.24)	0.18
	4	18/140 (12.9)	0.52 (0.25, 1.05)	0.07
Allergen sensitization	1	38/140 (27.1)	1 (Ref)	<b>0.86</b>
	2	37/134 (27.6)	1.09 (0.61, 1.96)	0.77
	3	35/138 (25.4)	0.91 (0.51, 1.62)	0.74
	4	36/140 (25.7)	0.86 (0.48, 1.52)	0.60
Medically diagnosed wheeze	1	13/141 (9.2)	1 (Ref)	<b>0.74</b>

2	10/140 (7.1)	0.82 (0.31, 2.13)	0.68
3	11/140 (7.9)	0.95 (0.39, 2.32)	0.91
4	15/140 (10.7)	1.33 (0.59, 3.04)	0.49

<sup>1</sup> Quartile 1 < 32.6 nmol/L; Q2 32.6 to 53.2 nmol/L; Q3 53.2 to 74.5 nmol/L; Q4 > 74.5 nmol/L

<sup>2</sup> Adjusted for maternal age, further maternal education after high school, maternal Caucasian ethnicity, infant sex, infant birth weight, infant GA at birth, maternal cat/dog ownership, parity > 1 and vaginal delivery

<sup>3</sup> Bolded p-values are for the global null hypothesis that the log odds of allergic disease are the same in the four quartiles

## References

1. Tulic MK, Hodder M, Forsberg A, McCarthy S, Richman T, D'Vaz N, van den Biggelaar AH, Thornton CA, Prescott SL. Differences in innate immune function between allergic and nonallergic children: new insights into immune ontogeny. *Journal of Allergy Clinical Immunology* 2011;127(2):470-8. e1.
2. Osborne NJ, Koplin JJ, Martin PE, Gurrin LC, Lowe AJ, Matheson MC, Ponsonby A-L, Wake M, Tang ML, Dharmage SCJJoA. Prevalence of challenge-proven IgE-mediated food allergy using population-based sampling and predetermined challenge criteria in infants. *J Journal of Allergy Clinical Immunology* 2011;127(3):668-76. e2.
3. Prescott S, Allen KJ. Food allergy: riding the second wave of the allergy epidemic. *Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology* 2011;22(2):155-60. doi: 10.1111/j.1399-3038.2011.01145.x.
4. Mullins RJ, Dear KB, Tang ML. Time trends in Australian hospital anaphylaxis admissions in 1998-1999 to 2011-2012. *J Allergy Clin Immunol* 2015;136(2):367-75. doi: 10.1016/j.jaci.2015.05.009.
5. Pfefferle PI, Buchele G, Blumer N, Roponen M, Ege MJ, Krauss-Etschmann S, Genuneit J, Hyvarinen A, Hirvonen MR, Lauener R, et al. Cord blood cytokines are modulated by maternal farming activities and consumption of farm dairy products during pregnancy: the PASTURE Study. *J Allergy Clin Immunol* 2010;125(1):108-15 e1-3. doi: 10.1016/j.jaci.2009.09.019.
6. Australia GoS. South Australian Perinatal Practice Guidelines - Vitamin and mineral supplementation in pregnancy. In: Ageing DfHa, ed.: SA Maternal & Neonatal Clinical Network 2015.
7. Houk VN, Oakley GP, Erickson JD, Mulinare J, James LM. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. 1992.
8. Group MVSr. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group. *Lancet* 1991;338(8760):131-7. doi: 10.1016/0140-6736(91)90133-a.
9. Berry RJ, Li Z, Erickson JD, Li S, Moore CA, Wang H, Mulinare J, Zhao P, Wong LY, Gindler J, et al. Prevention of neural-tube defects with folic acid in China. China-U.S. Collaborative Project for Neural Tube Defect Prevention. *N Engl J Med* 1999;341(20):1485-90. doi: 10.1056/NEJM199911113412001.
10. Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. *N Engl J Med* 1992;327(26):1832-5. doi: 10.1056/NEJM199212243272602.
11. Initiative FF. Global Progress of Industrially Milled Cereal Grains. 2019.
12. Hollingsworth JW, Maruoka S, Boon K, Garantziotis S, Li Z, Tomfohr J, Bailey N, Potts EN, Whitehead G, Brass DM, et al. In utero supplementation with methyl donors enhances allergic airway disease in mice. *J Clin Invest* 2008;118(10):3462-9. doi: 10.1172/JCI34378.

13. Yang L, Jiang L, Bi M, Jia X, Wang Y, He C, Yao Y, Wang J, Wang Z. High dose of maternal folic acid supplementation is associated to infant asthma. *Food Chem Toxicol* 2015;75:88-93. doi: 10.1016/j.fct.2014.11.006.
14. Bekkers MB, Elstgeest LE, Scholtens S, Haveman-Nies A, de Jongste JC, Kerkhof M, Koppelman GH, Gehring U, Smit HA, Wijga AH. Maternal use of folic acid supplements during pregnancy, and childhood respiratory health and atopy. *European Respiratory Journal* 2012;39(6):1468-74.
15. Whitrow MJ, Moore VM, Rumbold AR, Davies MJ. Effect of supplemental folic acid in pregnancy on childhood asthma: a prospective birth cohort study. *Am J Epidemiol* 2009;170(12):1486-93. doi: 10.1093/aje/kwp315.
16. Haberg SE, London SJ, Stigum H, Nafstad P, Nystad W. Folic acid supplements in pregnancy and early childhood respiratory health. *Arch Dis Child* 2009;94(3):180-4. doi: 10.1136/adc.2008.142448.
17. Kiefte-de Jong JC, Timmermans S, Jaddoe VW, Hofman A, Tiemeier H, Steegers EA, de Jongste JC, Moll HA. High Circulating Folate and Vitamin B-12 Concentrations in Women During Pregnancy Are Associated with Increased Prevalence of Atopic Dermatitis in Their Offspring. *The Journal of nutrition* 2012;142(4):731-8.
18. Dunstan JA, West C, McCarthy S, Metcalfe J, Meldrum S, Oddy WH, Tulic MK, D'Vaz N, Prescott SL. The relationship between maternal folate status in pregnancy, cord blood folate levels, and allergic outcomes in early childhood. *Allergy* 2012;67(1):50-7. doi: 10.1111/j.1398-9995.2011.02714.x.
19. Parr CL, Magnus MC, Karlstad O, Haugen M, Refsum H, Ueland PM, McCann A, Nafstad P, Haberg SE, Nystad W, et al. Maternal Folate Intake during Pregnancy and Childhood Asthma in a Population-based Cohort. *American journal of respiratory and critical care medicine* 2017;195(2):221-8. doi: 10.1164/rccm.201604-0788OC.
20. McGowan EC, Hong X, Selhub J, Paul L, Wood RA, Matsui EC, Keet CA, Wang X. Association Between Folate Metabolites and the Development of Food Allergy in Children. *The journal of allergy and clinical immunology In practice* 2020;8(1):132-40 e5. doi: 10.1016/j.jaip.2019.06.017.
21. Veeranki SP, Gebretsadik T, Mitchel EF, Tylavsky FA, Hartert TV, Cooper WO, Dupont WD, Dorris SL, Hartman TJ, Carroll KN. Maternal Folic Acid Supplementation During Pregnancy and Early Childhood Asthma. *Epidemiology* 2015;26(6):934-41. doi: 10.1097/EDE.0000000000000380.
22. Liu J, Li Z, Ye R, Liu J, Ren A. Periconceptional folic acid supplementation and risk of parent-reported asthma in children at 4–6 years of age. *J ERJ open research* 2020;6(1).
23. Zetstra-van der Woude PA, De Walle HE, Hoek A, Bos HJ, Boezen HM, Koppelman GH, de Jong-van den Berg LT, Scholtens S. Maternal high-dose folic acid during pregnancy and asthma medication in the offspring. *Pharmacoepidemiol Drug Saf* 2014;23(10):1059-65. doi: 10.1002/pds.3652.
24. Molloy AM, Kirke PN, Brody LC, Scott JM, Mills JL. Effects of folate and vitamin B12 deficiencies during pregnancy on fetal, infant, and child development. *Food Nutr Bull* 2008;29(2 Suppl):S101-11; discussion S12-5. doi: 10.1177/15648265080292S114.

25. Granell R, Heron J, Lewis S, Davey Smith G, Sterne JA, Henderson J. The association between mother and child MTHFR C677T polymorphisms, dietary folate intake and childhood atopy in a population-based, longitudinal birth cohort. *Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology* 2008;38(2):320-8. doi: 10.1111/j.1365-2222.2007.02902.x.
26. Fortes C, Mastroeni S, Mannooranparampil TJ, Di Lallo D. Pre-natal folic acid and iron supplementation and atopic dermatitis in the first 6 years of life. *Arch Dermatol Res* 2019;311(5):361-7. doi: 10.1007/s00403-019-01911-2.
27. Kim JH, Jeong KS, Ha EH, Park H, Ha M, Hong YC, Bhang SY, Lee SJ, Lee KY, Lee SH, et al. Relationship between prenatal and postnatal exposures to folate and risks of allergic and respiratory diseases in early childhood. *Pediatr Pulmonol* 2015;50(2):155-63. doi: 10.1002/ppul.23025.
28. Zhou SJ, Best K, Gibson R, McPhee A, Yelland L, Quinlivan J, Makrides M. Study protocol for a randomised controlled trial evaluating the effect of prenatal omega-3 LCPUFA supplementation to reduce the incidence of preterm birth: the ORIP trial. *BMJ Open* 2017;7(9):e018360. doi: 10.1136/bmjopen-2017-018360.
29. Valera-Gran D, Garcia de la Hera M, Navarrete-Munoz EM, Fernandez-Somoano A, Tardon A, Julvez J, Forn J, Lertxundi N, Ibarluzea JM, Murcia M, et al. Folic acid supplements during pregnancy and child psychomotor development after the first year of life. *JAMA Pediatr* 2014;168(11):e142611. doi: 10.1001/jamapediatrics.2014.2611.
30. West CE, Dunstan J, McCarthy S, Metcalfe J, D'Vaz N, Meldrum S, Oddy WH, Tulic MK, Prescott SL. Associations between maternal antioxidant intakes in pregnancy and infant allergic outcomes. *Nutrients* 2012;4(11):1747-58.
31. Pfeiffer CM, Fazili Z, McCoy L, Zhang M, Gunter EW. Determination of folate vitamers in human serum by stable-isotope-dilution tandem mass spectrometry and comparison with radioassay and microbiologic assay. *Clin Chem* 2004;50(2):423-32. doi: 10.1373/clinchem.2003.026955.
32. Nurmatov U, Nwaru BI, Devereux G, Sheikh A. Confounding and effect modification in studies of diet and childhood asthma and allergies. *Allergy* 2012;67(8):1041-59. doi: 10.1111/j.1398-9995.2012.02858.x.
33. Plumptre L, Masih SP, Ly A, Aufreiter S, Sohn KJ, Croxford R, Lausman AY, Berger H, O'Connor DL, Kim YI. High concentrations of folate and unmetabolized folic acid in a cohort of pregnant Canadian women and umbilical cord blood. *Am J Clin Nutr* 2015;102(4):848-57. doi: 10.3945/ajcn.115.110783.
34. Mullins RJ, Clark S, Camargo CA, Jr. Socio-economic status, geographic remoteness and childhood food allergy and anaphylaxis in Australia. *Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology* 2010;40(10):1523-32. doi: 10.1111/j.1365-2222.2010.03573.x.